Stock BODALCHEM BODAL CHEMICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bodal Chemicals Limited NSE India S.E.

Equities

BODALCHEM

INE338D01028

Delayed NSE India S.E.
Other stock markets
 07:42:29 2024-04-30 am EDT 		5-day change 1st Jan Change
77.8 INR -1.46% Intraday chart for Bodal Chemicals Limited -1.21% -5.93%
Mar. 06 Bodal Chemicals Limited announced that it expects to receive INR 214 million in funding CI
Feb. 13 Transcript : Bodal Chemicals Limited, Q3 2024 Earnings Call, Feb 13, 2024

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company sustains low margins.
  • With an expected P/E ratio at 129.77 and 21.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Specialty Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
BODAL CHEMICALS LIMITED Stock Bodal Chemicals Limited
-5.93% 117M -
ECOLAB INC. Stock Ecolab Inc.
+14.02% 64.66B
A-
SIKA AG Stock Sika AG
-3.80% 46.08B
A-
GIVAUDAN SA Stock Givaudan SA
+13.26% 39.72B
B+
FUJIFILM HOLDINGS CORPORATION Stock Fujifilm Holdings Corporation
+19.28% 25.82B
A-
EMS-CHEMIE HOLDING AG Stock EMS-CHEMIE HOLDING AG
+8.22% 18.8B
C+
CELANESE CORPORATION Stock Celanese Corporation
-1.13% 17.14B
B+
POSCO FUTURE M CO., LTD. Stock Posco Future M Co., Ltd.
-21.03% 15.86B
A-
SYMRISE AG Stock Symrise AG
+1.06% 15.05B
B+
ALBEMARLE CORPORATION Stock Albemarle Corporation
-16.73% 14.14B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. BODALCHEM Stock
  4. BODALCHEM Stock
  5. Ratings Bodal Chemicals Limited